Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US0028241000
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG000B9ZXB4
ABT
Abbott Laboratories
GICS: Health Care · SECTOR: Healthcare · SUB-SECTOR: Medical Devices · THEMEFOLIO: $HLTH
NAME
Abbott Laboratories
ISIN
US0028241000
TICKER
ABT
MIC
XNYS
REUTERS
ABT.N
BLOOMBERG
ABT US
Sat, 25.04.2026       Abbott Labs
US0028241000

Four late-breaking presentations at Heart Rhythm Society 2026 in Chicago highlight strong clinical evidence across Abbott's growing pulsed field ablation and novel cardiac pacing portfoliosSix-month results from the FlexPulse IDE study for the TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, reveal positive outcomes for treating complex AFib cas...
Read more
Abbott Labs
Technical Analysis Termsheets Terminal
Permalink
Fri, 17.04.2026       Abbott Labs
US0028241000

Data show how a multi-biomarker class approach improves early-stage cancer detectionAACR will also recognize landmark DETECT-A study publication reporting long-term outcomes supporting the clinical impact of MCEDABBOTT PARK, Ill., April 17, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) will present new data at the American Association for Cancer Researc...
Read more
Abbott Labs
Technical Analysis Termsheets Terminal
Permalink
Thu, 16.04.2026       Abbott Labs
US0028241000

First-quarter GAAP diluted EPS of $0.61; adjusted diluted EPS of $1.15 reflects growth of 6 percentCompleted acquisition of Exact Sciences, establishing Abbott as a leader in the fast-growing oncology diagnostics marketAbbott projects full-year 2026 comparable sales growth of 6.5% to 7.5%1Abbott projects full-year 2026 adjusted diluted EPS of $5.3...
Read more
Abbott Labs
Technical Analysis Termsheets Terminal
Permalink
Tue, 14.04.2026       Abbott Labs
US0028241000

Das Instrument ABL US0028241000 ABBOTT LABS EQUITY wird ex Dividende/Zinsen gehandelt am 15.04.2026 The instrument ABL US0028241000 ABBOTT LABS EQUITY has its ex-dividend/interest day on 15.04.2026...
Read more
Abbott Labs
Technical Analysis Termsheets Terminal
Permalink
Mon, 13.04.2026       Abbott Labs
US0028241000

Das Instrument ABL US0028241000 ABBOTT LABS EQUITY wird cum Dividende/Zinsen gehandelt am 14.04.2026 und ex Dividende/Zinsen am 15.04.2026 The instrument ABL US0028241000 ABBOTT LABS EQUITY has its pre-dividend/interest day on 14.04.2026 and its ex-dividend/interest day on 15.04.2026...
Read more
Abbott Labs
Technical Analysis Termsheets Terminal
Permalink
Mon, 13.04.2026       Abbott Labs
US0028241000

Das Instrument ABL US0028241000 ABBOTT LABS EQUITY wird cum Dividende/Zinsen gehandelt am 14.04.2026 und ex Dividende/Zinsen am 15.04.2026 The instrument ABL US0028241000 ABBOTT LABS EQUITY has its pre-dividend/interest day on 14.04.2026 and its ex-dividend/interest day on 15.04.2026...
Read more
Abbott Labs
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.04.2026       Abbott Labs
US0028241000

With chronic disease on the rise, a new survey from Abbott shows information overload, confusion and cost leave many Americans struggling, worrying about how to stay healthyABBOTT PARK, Ill., April 9, 2026 /PRNewswire/ -- Today, Abbott (NYSE: ABT), a global leader in chronic disease prevention, treatment and care, is releasing new survey findings...
Read more
Abbott Labs
Technical Analysis Termsheets Terminal
Permalink
Mon, 30.03.2026       Abbott Labs
US0028241000

Broadens access to Abbott's Precision Oncology tests across more than 1,600 community cancer care centers and 4,700 providers in Flatiron's North America network, helping accelerate informed treatment decisionsAllows oncologists to order tests and view results directly in the clinical workflowABBOTT PARK, Ill. and NEW YORK, March 30, 2026 /PRNewsw...
Read more
Abbott Labs
Technical Analysis Termsheets Terminal
Permalink
Thu, 26.03.2026       Abbott Labs
US0028241000

ABBOTT PARK, Ill., March 26, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its first-quarter 2026 financial results on Thursday, April 16, before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Rela...
Read more
Abbott Labs
Technical Analysis Termsheets Terminal
Permalink
Tue, 24.03.2026       Abbott Labs
US0028241000

Potentially awkward conversations and 90s nostalgia combine to drive accessible screening for adults 45+Learn more at Cologuard.com/TheTalkABBOTT PARK, Ill., March 24, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced a new campaign encouraging people to stop avoiding awkward conversations about colorectal cancer. The company is reuniting be...
Read more
Abbott Labs
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Mon, 23.03.2026       Abbott Labs
US0028241000

Establishes Abbott as a leader in fast-growing cancer screening and diagnostics segmentsAdvances Abbott's mission to make healthcare more accessible and give people more control over their healthABBOTT PARK, Ill., March 23, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has completed the acquisition of Exact Sciences, establishing Abbo...
Read more
Abbott Labs
Technical Analysis Termsheets Terminal
Permalink
Fri, 20.03.2026       Abbott Labs
US0028241000

Announcement follows receipt of all regulatory clearances necessary for closingTransaction enables Abbott to enter and lead in fast-growing cancer screening and diagnostics segments, serving millions of additional peopleABBOTT PARK, Ill., March 20, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that it expects to close the acquisition of...
Read more
Abbott Labs
Technical Analysis Termsheets Terminal
Permalink
Thu, 12.03.2026       Abbott Labs
US0028241000

U.K. FreeDM2 randomized controlled trial: At four months, people using Libre technology had a 0.6% greater reduction in HbA1c and 2.5 more hours a day in the healthy range vs. fingersticks 1,2Improvements were participant-led, using real-time glucose readings to guide everyday decisionsComplementary Italian study reported similar improvements, rei...
Read more
Abbott Labs
Technical Analysis Termsheets Terminal
Permalink
Thu, 12.03.2026       Abbott Labs
US0028241000

Eine randomisierte kontrollierte FreeDM2-Studie aus Großbritannien belegt: Nach vier Monaten hatten Personen, die die FreeStyle Libre Technologie nutzten, eine um 0,6 % stärkere HbA1c-Reduktion und 2,5 Stunden pro Tag mehr im Zielbereich im Vergleich zu Blutzuckermessungen per Fingerstich1,2Verbesserungen wurden von den Teilnehmenden selbst erziel...
Read more
Abbott Labs
Technical Analysis Termsheets Terminal
Permalink
Thu, 12.03.2026       Abbott Labs
US0028241000

Eine randomisierte kontrollierte FreeDM2-Studie aus Großbritannien belegt: Nach vier Monaten hatten Personen, die die FreeStyle Libre Technologie nutzten, eine um 0,6 % stärkere HbA1c-Reduktion und 2,5 Stunden pro Tag mehr im Zielbereich im Vergleich zu Blutzuckermessungen per Fingerstich1,2Verbesserungen wurden von den Teilnehmenden selbst erzie...
Read more
Abbott Labs
Technical Analysis Termsheets Terminal
Permalink
Thu, 12.03.2026       Abbott Labs
US0028241000

U.K. FreeDM2 randomized controlled trial: At four months, people using Libre technology had a 0.6% greater reduction in HbA1c and 2.5 more hours a day in the healthy range vs. fingersticks 1,2Improvements were participant-led, using real-time glucose readings to guide everyday decisionsComplementary Italian study reported similar improvements, rei...
Read more
Abbott Labs
Technical Analysis Termsheets Terminal
Permalink
Wed, 11.03.2026       Abbott Labs
US0028241000

Abbott, in collaboration with Real Madrid, will host free selection events combining soccer and health education to identify the second annual 'Abbott Dream Team'All participants will receive sports nutrition guidance from Abbott experts and take part in on-field development sessions led by Real Madrid coachesThe 16 selected male and female 'Abbot...
Read more
Abbott Labs
Technical Analysis Termsheets Terminal
Permalink
Fri, 20.02.2026       Abbott Labs
US0028241000

ABBOTT PARK, Ill., Feb. 20, 2026 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 63 cents per share. This marks the 409th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable May 15, 2026, to shareholders of record at the close of business on April 1...
Read more
Abbott Labs
Technical Analysis Termsheets Terminal
Permalink
Fri, 06.02.2026       Abbott Labs
US0028241000

Positive 12-month results from the VOLT-AF IDE Study presented at the AF Symposium and simultaneously published in JACC: Clinical Electrophysiology, reinforce the Volt™ Pulsed Field Ablation (PFA) System's industry-leading success rate for treating AFib1New data from the FOCALFLEX CE Mark trial demonstrate the safety and efficacy of the TactiFlex™...
Read more
Abbott Labs
Technical Analysis Termsheets Terminal
Permalink
Thu, 22.01.2026       Abbott Labs
US0028241000

Fourth-quarter GAAP diluted EPS of $1.01; adjusted diluted EPS of $1.50 reflects growth of 12 percentFull-year 2025 GAAP diluted EPS of $3.72; adjusted diluted EPS of $5.15 reflects growth of 10 percentAbbott projects full-year 2026 organic sales growth to be in the range of 6.5% to 7.5%Abbott projects full-year 2026 adjusted diluted EPS of $5.55...
Read more
Abbott Labs
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Tue, 20.01.2026       Abbott Labs
US0028241000

Abbott's TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, is designed with dual-energy to treat atrial fibrillation patients with the most challenging casesIt can deliver both radiofrequency energy and pulsed field ablation (PFA) energy during procedures to target and treat an irregular heart rhythmThe availability of TactiFlex Duo in Europe add...
Read more
Abbott Labs
Technical Analysis Termsheets Terminal
Permalink
Tue, 13.01.2026       Abbott Labs
US0028241000

Das Instrument ABL US0028241000 ABBOTT LABS EQUITY wird cum Dividende/Zinsen gehandelt am 14.01.2026 und ex Dividende/Zinsen am 15.01.2026 The instrument ABL US0028241000 ABBOTT LABS EQUITY has its pre-dividend/interest day on 14.01.2026 and its ex-dividend/interest day on 15.01.2026...
Read more
Abbott Labs
Technical Analysis Termsheets Terminal
Permalink
Wed, 07.01.2026       Abbott Labs
US0028241000

Coverage means more Canadians with diabetes can access Abbott's sensor-based glucose technology, giving them actionable insights to manage their condition confidently,iAbbott's latest innovation, the FreeStyle Libre 3 Plus* sensor, is easy to apply, ii easy to useiii and features the world's smallest glucose sensor, iv,v providing users with accur...
Read more
Abbott Labs
Technical Analysis Termsheets Terminal
Permalink
Mon, 05.01.2026       Abbott Labs
US0028241000

ABBOTT PARK, Ill., Jan. 5, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its fourth-quarter 2025 financial results on Thursday, Jan. 22, before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relati...
Read more
Abbott Labs
Technical Analysis Termsheets Terminal
Permalink
Mon, 05.01.2026       Abbott Labs
US0028241000

Traditional food logging apps offer feedback after the fact—Libre Assist1 offers help in-the-moment to inform mealtime decisions before every biteLibre Assist1 leverages AI to predict how food choices affect glucose levels,2 provides personalized meal guidance,3 and confirms glucose impact using data from Abbott's world-leading FreeStyle Libre con...
Read more
Abbott Labs
Technical Analysis Termsheets Terminal
Permalink
Mon, 22.12.2025       Abbott Labs
US0028241000

Abbott's Volt™ PFA System, the latest generation of cardiac ablation technology, is designed for people battling heart rhythm disorders such as atrial fibrillation (AFib)Pulsed field ablation – or PFA – is a minimally invasive procedure that uses high-energy electrical pulses in targeted areas of the heart to treat irregular heart rhythmsAbbott's...
Read more
Abbott Labs
Technical Analysis Termsheets Terminal
Permalink
Thu, 18.12.2025       Abbott Labs
US0028241000

First and only delivery system designed specifically for premature infants with a patent ductus arteriosus (PDA), a life-threatening opening in their heartNew delivery system enables precise placement of Abbott's Amplatzer Piccolo Occluder in the tiniest babiesA PDA requiring treatment is present in approximately 20% of premature infants1ABBOTT PA...
Read more
Abbott Labs
Technical Analysis Termsheets Terminal
Permalink
Fri, 12.12.2025       Abbott Labs
US0028241000

Quarterly dividend increased by 6.8%Quarterly dividend payout has increased more than 70% since 2020408th consecutive quarterly dividend to be paid by Abbott since 1924ABBOTT PARK, Ill., Dec. 12, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that its board of directors has increased the company's quarterly common dividend to 63 cents per...
Read more
Abbott Labs
Technical Analysis Termsheets Terminal
Permalink
Fri, 12.12.2025       Abbott Labs
US0028241000

ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD.VANCOUVER, BC, Dec. 12, 2025 /PRNewswire/ -- USANewsGroup.com News Commentary – Point-of-care infectious disease diagnostics valued at $53 billion in 2024 are projected to nearly double by 2033, driven by AI systems that deliver laboratory-grade results at the bedside[1]. Meanwhile, healthcare organi...
Read more
Abbott Labs
Technical Analysis Termsheets Terminal
Permalink
Fri, 12.12.2025       Abbott Labs
US0028241000

ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD.VANCOUVER, BC, Dec. 12, 2025 /CNW/ -- USANewsGroup.com News Commentary – Point-of-care infectious disease diagnostics valued at $53 billion in 2024 are projected to nearly double by 2033, driven by AI systems that deliver laboratory-grade results at the bedside[1]. Meanwhile, healthcare organizations...
Read more
Abbott Labs
Technical Analysis Termsheets Terminal
Permalink
Mon, 08.12.2025       Abbott Labs
US0028241000

Lingo, Abbott's first over-the-counter biowearable, expands to Android devicesContinuous glucose monitoring devices help people maintain healthy glucose levels, which are associated with better metabolic health and lower long-term risk of chronic conditionsNew data from Lingo users highlight how protein supplementation is linked to lower glucose i...
Read more
Abbott Labs
Technical Analysis Termsheets Terminal
Permalink
Sun, 07.12.2025       Abbott Labs
US0028241000

University of Wisconsin wins Abbott and the Big Ten Conference's "We Give Blood" drive, awards $1 million from Abbott to advance student or community healthSecond year of nationwide blood drive saw a 319% increase in overall participation with 83,043 donations and a 168% jump in student donors compared to 2024Big Ten students, alumni, and fans hel...
Read more
Abbott Labs
Technical Analysis Termsheets Terminal
Permalink
Thu, 04.12.2025       Abbott Labs
US0028241000

Aging, nutrition and lifestyle affect muscles, especially after age 40. That's why Matt Ryan, former professional quarterback and MVP, is teaming up with Abbott to drive muscle health awareness with two new Ensure Max Protein shakesEnsure Max Protein 42g: For physically active adults, this new shake delivers 42 grams of complete protein to help bu...
Read more
Abbott Labs
Technical Analysis Termsheets Terminal
Permalink
Thu, 20.11.2025       Abbott Labs
US0028241000

Acquisition adds a new growth vertical to Abbott's already high single-digit growth profile, gaining leadership in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics segments Acquisition will uniquely position Abbott to transform cancer care, advancing earlier...
Read more
Abbott Labs
Technical Analysis Termsheets Terminal
Permalink
Tue, 04.11.2025       Abbott Labs
US0028241000

Movie to feature cameos from youth who have overcome significant heart health challenges and are part of the Abbott HeartMates community as well as professional football player and HeartMates ambassador Damar Hamlin "The More the Merrier" is the first Hallmark m...
Read more
Abbott Labs
Technical Analysis Termsheets Terminal
Permalink
Wed, 15.10.2025       Abbott Labs
US0028241000

Third-quarter reported sales growth of 6.9 percent; organic sales growth of 5.5 percent or 7.5 percent excluding COVID-19 testing-related sales1 Third-quarter GAAP diluted EPS of $0.94; adjusted diluted EPS of $1.30...
Read more
Abbott Labs
Technical Analysis Termsheets Terminal
Permalink
Mon, 13.10.2025       Abbott Labs
US0028241000

Das Instrument ABL US0028241000 ABBOTT LABS EQUITY wird cum Dividende/Zinsen gehandelt am 14.10.2025 und ex Dividende/Zinsen am 15.10.2025 The instrument ABL US0028241000 ABBOTT LABS EQUITY has its pre-dividend/interest day on 14.10.2025 and its ex-dividend/interest day on 15.10.2025...
Read more
Abbott Labs
Technical Analysis Termsheets Terminal
Permalink
Mon, 29.09.2025       Abbott Labs
US0028241000

More than 800,000 Canadians1 live with peripheral artery disease (PAD) with limited treatment options to date1 The first-of-its-kind dissolvable stent, the Esprit™ BTK Everolimus Eluting Resorbable Scaffold, dissolves over time after it has opened blocked arteries below-the-knee (BTK)...
Read more
Abbott Labs
Technical Analysis Termsheets Terminal
Permalink
Wed, 24.09.2025       Abbott Labs
US0028241000

ABBOTT PARK, Ill., Sept. 24, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its third-quarter 2025 financial results on Wednesday, Oct. 15, before the market opens.  The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor R...
Read more
Abbott Labs
Technical Analysis Termsheets Terminal
Permalink
Fri, 19.09.2025       Abbott Labs
US0028241000

ABBOTT PARK, Ill., Sept. 19, 2025 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 59 cents per share. This marks the 407th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Nov. 17, 2025, to shareholders of record at the close of business on Oct...
Read more
Abbott Labs
Technical Analysis Termsheets Terminal
Permalink
Fri, 29.08.2025       Abbott Labs
US0028241000

Navitor is now approved as a minimally invasive alternative to surgery for patients in Europe with symptomatic, severe aortic stenosis (a common and life-threatening heart valve disease) who are at low or intermediate surgical riskCE Mark is based on safety and effectiveness data from the VANTAGE trial presented at the European Society of Cardi...
Read more
Abbott Labs
Technical Analysis Termsheets Terminal
Permalink
Tue, 26.08.2025       Abbott Labs
US0028241000

Abbott's denosumab biosimilar is the first approved in Thailand, making advanced therapy for osteoporosis and cancer-related bone loss more affordable for millions of ThaisThis approval builds on Abbott's biosimilar portfolio in Asia Pacific, following recent launches in Malaysia and IndiaBANGKOK, Aug. 26, 2025 /PRNewswire/ -- Abbott (NYSE: ABT),...
Read more
Abbott Labs
Technical Analysis Termsheets Terminal
Permalink
Tue, 26.08.2025       Abbott Labs
US0028241000

Abbott's denosumab biosimilar is the first approved in Thailand, making advanced therapy for osteoporosis and cancer-related bone loss more affordable for millions of ThaisThis approval builds on Abbott's biosimilar portfolio in Asia Pacific, following recent launches in Malaysia and IndiaBANGKOK, Aug. 26, 2025 /PRNewswire/ -- Abbott (NYSE: ABT),...
Read more
Abbott Labs
Technical Analysis Termsheets Terminal
Permalink
Mon, 18.08.2025       Abbott Labs
US0028241000

All 18 Big Ten universities will go head-to-head in Year 2 of the nationwide challenge, the 'We Give Blood' drive, to inspire the most blood donations from students, alumni, and fans with the winning school earning $1 million from Abbott for student or community healthAbbott is releasing exclusive, limited-edition Homefield designed T-shirts fo...
Read more
Abbott Labs
Technical Analysis Termsheets Terminal
Permalink
Thu, 17.07.2025       Abbott Labs
US0028241000

Second-quarter reported sales growth of 7.4 percent; organic sales growth of 6.9 percent or 7.5 percent excluding COVID-19 testing-related sales1Second-quarter GAAP diluted EPS of $1.01; adjusted diluted EPS of $1.26Reported gross margin of 52.7 percent of sales; adjusted gross margin of 57.0 percent, which reflects a 100 basis point increaseRepo...
Read more
Abbott Labs
Technical Analysis Termsheets Terminal
Permalink
Tue, 15.07.2025       Abbott Labs
US0028241000

MarketNewsUpdates News Commentary NEW YORK, July 15, 2025 /PRNewswire/ -- Artificial Intelligence (AI) algorithms are revolutionizing the way retina images are analyzed for detecting conditions such as age-related macular degeneration (AMD) and diabetic retinopathy. These advanced algorithms often achieve diagnostic accuracies that equal or surpa...
Read more
Abbott Labs
Technical Analysis Termsheets Terminal
Permalink
Tue, 15.07.2025       Abbott Labs
US0028241000

MarketNewsUpdates News Commentary NEW YORK, July 15, 2025 /CNW/ -- Artificial Intelligence (AI) algorithms are revolutionizing the way retina images are analyzed for detecting conditions such as age-related macular degeneration (AMD) and diabetic retinopathy. These advanced algorithms often achieve diagnostic accuracies that equal or surpass huma...
Read more
Abbott Labs
Technical Analysis Termsheets Terminal
Permalink
Tue, 15.07.2025       Abbott Labs
US0028241000

MarketNewsUpdates News Commentary NEW YORK, July 15, 2025 /PRNewswire/ -- Artificial Intelligence (AI) algorithms are revolutionizing the way retina images are analyzed for detecting conditions such as age-related macular degeneration (AMD) and diabetic retinopathy. These advanced algorithms often achieve diagnostic accuracies that equal or surpa...
Read more
Abbott Labs
Technical Analysis Termsheets Terminal
Permalink
Tue, 08.07.2025       Abbott Labs
US0028241000

Abbott continues to transform diabetes care with its leading Libre systems and the new FreeStyle Libre 3 Plus* sensor MISSISSAUGA, ON, July 8, 2025 /CNW/ -- Abbott (NYSE: ABT) today announced that its latest generation of sensor-based glucose monitoring technology, the FreeStyle Libre 3 Plus* sensor, is now available to Canadians living with diab...
Read more
Abbott Labs
Technical Analysis Termsheets Terminal
Permalink
Tue, 08.07.2025       Abbott Labs
US0028241000

Abbott continues to transform diabetes care with its leading Libre systems and the new FreeStyle Libre 3 Plus* sensor MISSISSAUGA, ON, July 8, 2025 /CNW/ -- Abbott (NYSE: ABT) today announced that its latest generation of sensor-based glucose monitoring technology, the FreeStyle Libre 3 Plus* sensor, is now available to Canadians living with diab...
Read more
Abbott Labs
Technical Analysis Termsheets Terminal
Permalink